Hikma Pharmaceuticals Plc engages in developing, manufacturing, and marketing branded and non-branded generic pharmaceutical products. Its pharmaceutical operations are conducted through three business segments: Injectables, Branded and Generics. The company supplies hospitals across its markets with generic and specialty injectable products, supported by its manufacturing facilities in the United States (US), Europe and Middle East/North Africa (MENA). The company supplies branded generic and in-licensed patented products from its local manufacturing facilities to retail and hospital customers across the MENA region. The company supplies oral, respiratory and other generic and specialty products to the North American retail market. Its manufacturing facilities in the US supply generic and specialty products to the US and Canada markets across a broad range of therapeutic areas, including respiratory, oncology and pain management.
How did HKMPY's recent EPS compare to expectations?
The most recent EPS for Hikma Pharmaceuticals PLC is $, expectations of $.
How did Hikma Pharmaceuticals PLC HKMPY's revenue perform in the last quarter?
Hikma Pharmaceuticals PLC revenue for the last quarter is $
What is the revenue estimate for Hikma Pharmaceuticals PLC?
According to of Wall street analyst, the revenue estimate of Hikma Pharmaceuticals PLC range from $ to $
What's the earning quality score for Hikma Pharmaceuticals PLC?
Hikma Pharmaceuticals PLC has a earning quality score of /. The score is based on a four dimension of Profitability, Growth, Cash generation & Capital Allocation, and Leverage.
When does Hikma Pharmaceuticals PLC report earnings?
Hikma Pharmaceuticals PLC next earnings report is expected in 2026-05-27
What are Hikma Pharmaceuticals PLC's expected earnings?
Hikma Pharmaceuticals PLC expected earnings is $, according to wall-street analysts.
Did Hikma Pharmaceuticals PLC beat earnings expectations?
Hikma Pharmaceuticals PLC recent earnings of $ expectations.